Drugs / CBP-1018
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04928612 | Nov 2021 → Oct 2024 overdue | neoplasm | Coherent Biopharma (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2024-06-05 | Coherent Biopharma (Suzhou) Co., Ltd. | Results ASCO 2024 Highlights: Research findings of CBP-1008 and CBP-1018 once again attract global attention coherentbio.com ↗
At this year’s ASCO 2024, Coherent Biopharma once again announced the research results of its two core self-developed products, CBP-1008 and CBP-1018. |
| 2023-10-20 | Coherent Biopharma (Suzhou) Co., Ltd. | Results Bi-XDC makes debut at the 14th World ADC Conference coherentbio.com ↗
Furthermore, CBP-1018, the world’s first PSMA/FRα dual-targeted ligand drug conjugate, has demonstrated efficacy and a favorable safety profile in patients with advanced prostate cancer. |
| 2023-06-06 | Coherent Biopharma (Suzhou) Co., Ltd. | Results Coherent Biopharma completed phase I clinical trial of CBP-1018, the world’s first dual-ligand conjugate drug targeting PSMA and FRα, in China coherentbio.com ↗
Notably, adverse events related to CBP-1018 treatment were manageable, and no DLT events were observed in any of the dose groups. |
| 2021-07-09 | Coherent Biopharma (Suzhou) Co., Ltd. | Regulatory Coherent Biopharma received IND study may proceed letter (study permission) from US FDA for its bi-ligand drug conjugate CBP-1018 coherentbio.com ↗
Coherent Biopharma’s another BEST TM （Bi-Engaging ligand-mediated Selective Targeting）platform pipeline investigational drug, CBP-1018, received study permission (Study May Proceed Letter) from US FDA on July 7, 2021. |
| 2020-09-01 | Coherent Biopharma (Suzhou) Co., Ltd. | Regulatory CBP-1018 Approved by NMPA for Clinical Trials coherentbio.com ↗
On November 4, 2020, Notice on Approval for Drug Clinical Trial was issued by NMPA for CBP-1018, the second bi-engaging ligand-mediated selective targeting drug conjugate developed by Coherent Biopharma. |
All press releases naming this drug 6 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CBP-1018 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04928612 ↗ |
| Modality | Other / unclassified | “bi-ligand-drug conjugate CBP-1018” NCT04928612 ↗ |
| Route | Intravenous | “CBP-1018 for injection, IV infusion” NCT04928612 ↗ |